Matches in Nanopublications for { ?s ?p "[To this end, experience with DNMT inhibitors in hematologic malignancies other than MDS is reviewed in an effort to better understand the therapeutic potential of these agents and to define areas of future exploration in these settings.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 10 of
10
with 100 items per page.
- NP914152.RAX2VyK7PZ5M0cAZ2YDWa8eXMA0XeDnXzYvsH5Jk1CZ5g130_assertion description "[To this end, experience with DNMT inhibitors in hematologic malignancies other than MDS is reviewed in an effort to better understand the therapeutic potential of these agents and to define areas of future exploration in these settings.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914152.RAX2VyK7PZ5M0cAZ2YDWa8eXMA0XeDnXzYvsH5Jk1CZ5g130_provenance.
- NP606106.RAceUnb6kmnBSSKrFukM8g33YBI5hyxFRN31Y9IEpxBcU130_assertion description "[To this end, experience with DNMT inhibitors in hematologic malignancies other than MDS is reviewed in an effort to better understand the therapeutic potential of these agents and to define areas of future exploration in these settings.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP606106.RAceUnb6kmnBSSKrFukM8g33YBI5hyxFRN31Y9IEpxBcU130_provenance.
- NP873280.RASsa05VPcPUOEiPNNhtIqNiTRUEK893odByHpYYFrTn8130_assertion description "[To this end, experience with DNMT inhibitors in hematologic malignancies other than MDS is reviewed in an effort to better understand the therapeutic potential of these agents and to define areas of future exploration in these settings.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873280.RASsa05VPcPUOEiPNNhtIqNiTRUEK893odByHpYYFrTn8130_provenance.
- NP526336.RASVs0ZYrfIvofjF5DJgRPZeI7gP4RDvE4Qz8Rc_ZO1OI130_assertion description "[To this end, experience with DNMT inhibitors in hematologic malignancies other than MDS is reviewed in an effort to better understand the therapeutic potential of these agents and to define areas of future exploration in these settings.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526336.RASVs0ZYrfIvofjF5DJgRPZeI7gP4RDvE4Qz8Rc_ZO1OI130_provenance.
- NP526346.RATTE6kMutt57pW7LHEeKS_8qClKWuhM_Ajjl8kX1GFis130_assertion description "[To this end, experience with DNMT inhibitors in hematologic malignancies other than MDS is reviewed in an effort to better understand the therapeutic potential of these agents and to define areas of future exploration in these settings.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526346.RATTE6kMutt57pW7LHEeKS_8qClKWuhM_Ajjl8kX1GFis130_provenance.
- NP526342.RADeTdvUtTXjF6akvd9sW_MdLhOLWUjoBQI26E-rPmFsw130_assertion description "[To this end, experience with DNMT inhibitors in hematologic malignancies other than MDS is reviewed in an effort to better understand the therapeutic potential of these agents and to define areas of future exploration in these settings.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526342.RADeTdvUtTXjF6akvd9sW_MdLhOLWUjoBQI26E-rPmFsw130_provenance.
- NP978630.RApbolxr-eJrIj1S2nCX0VuiTHTyImgy3VvPHjJcWqOPw130_assertion description "[To this end, experience with DNMT inhibitors in hematologic malignancies other than MDS is reviewed in an effort to better understand the therapeutic potential of these agents and to define areas of future exploration in these settings.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978630.RApbolxr-eJrIj1S2nCX0VuiTHTyImgy3VvPHjJcWqOPw130_provenance.
- NP526339.RArLZsoHOfiLLzQFNZrNU21a7vYZPRGHH4fYJhfk7F0oI130_assertion description "[To this end, experience with DNMT inhibitors in hematologic malignancies other than MDS is reviewed in an effort to better understand the therapeutic potential of these agents and to define areas of future exploration in these settings.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526339.RArLZsoHOfiLLzQFNZrNU21a7vYZPRGHH4fYJhfk7F0oI130_provenance.
- NP526340.RAln6B7oxx9_SliLTm1sBBDEdUjeSHP5iiqqQhv5yspz0130_assertion description "[To this end, experience with DNMT inhibitors in hematologic malignancies other than MDS is reviewed in an effort to better understand the therapeutic potential of these agents and to define areas of future exploration in these settings.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526340.RAln6B7oxx9_SliLTm1sBBDEdUjeSHP5iiqqQhv5yspz0130_provenance.
- NP781536.RAJDcYsebZUDp0lLfZCxlwFWbapWdt1YwpbR7YJ1SLTOA130_assertion description "[To this end, experience with DNMT inhibitors in hematologic malignancies other than MDS is reviewed in an effort to better understand the therapeutic potential of these agents and to define areas of future exploration in these settings.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781536.RAJDcYsebZUDp0lLfZCxlwFWbapWdt1YwpbR7YJ1SLTOA130_provenance.